Previous 10 | Next 10 |
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, this morning announced the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. Dr. Abrams is an assistant professor of orthopedic su...
LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical ® therapeutic devices, today announces the appointment of orthopedic surgeon Dr. Geoffr...
More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018 Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving ...
A rapidly aging population and technological advances are contributing to the fast growth of the global pain management device market The market is currently dominated by neurostimulation devices, which accounted for half the revenue reported in 2018 – a trend that’s likely ...
Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross prof...
LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Endonovo Therapeutics, Inc . (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the second quarter ended June 30, 2019. Alan Collier, Endonovo’s chief executive of...
Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. An article discussing the company reads, “SofPulse was recently...
Endonovo Therapeutics (OTCQB: ENDV) is a commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices that target patient pain and inflammation while supporting wound recovery. An article discussing the company reads, “Targeting inflammatory conditions in vital or...
NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Endonovo Therapeutics Inc. (OTCQB: ENDV), an innovative biotechnology company and commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the broadcast of its exclusive a...
While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of o...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...